Establishment and validation of quantitative real-time pcr assay for aberrant methylation of 14-3-3û gene in breast and lung carcinoma

Cancer Genomics and Proteomics

Volumn 1, Issue 1, 2004, Pages 1-8

  Sathyanarayana, Ubaradka G ^a   Suzuki, Makoto ^a   Toyooka, Shinichi ^a   Padar, Asha ^a   Toyooka, Kiyomi O ^a   Zern, Andrea L ^a   Miyajima, Kuniharu ^a   Takahashi, Takashi ^b   Brambilla, Elizabeth ^c   Gazdar, Adi F ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

14 3 3 ; Breast cancer; Lung cancer; Methylation; MSP; Real Time PCR

Indexed keywords

EID: 13844263362     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW and Vogelstein B: 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1: 3-11, 1997.
2. el-Deiry WS: Regulation of p53 downstream genes. Semin. Cancer Biol 8: 345-357, 1998.
3. Chan TA, Hermeking H, Lengauer C, Kinzler KW and Vogelstein B: 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 401: 616-620, 1999.
4. Piwnica-Worms H: Cell cycle. Fools rush in. Nature 401: 535-537, 1999.
5. Prasad GL, Valverius EM, McDuffie E and Cooper HL: Complementary DNA cloning of a novel epithelial cell marker protein, HME1, that may be down-regulated in neoplastic mammary cells. Cell Growth Differ 3: 507-513, 1992.
6. Vellucci VF, Germino FJ and Reiss M: Cloning of putative growth regulatory genes from primary human keratinocytes by subtractive hybridization. Gene 166: 213-220, 1995.
7. Shapiro GI, Park JE, Edwards CD, Mao L, Merlo A, Sidransky D, Ewen ME and Rollins BJ: Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines. Cancer Res 55: 6200-6209, 1995.
8. Baylin SB, Herman JG, Graff JR, Vertino PM and Issa JP: Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72: 141-196, 1998.
9. Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomaki P, Lang JC, Schuller DE, Yu L, Bloomfield CD, Caligiuri MA, Yates A, Nishikawa R, Su Huang H, Petrelli NJ, Zhang X, O'Dorisio MS, Held WA, Cavenee WK and Plass C: Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 24: 132-138, 2000.
10. Esteller M: CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 21: 5427-5440, 2002.
11. Dellambra E, Patrone M, Sparatore B, Negri A, Ceciliani F, Bondanza S, Molina F, Cancedda FD and De Luca M: Stratifin, a keratinocyte specific 14-3-3 protein, harbors a pleckstrin homology (PH) domain and enhances protein kinase C activity. J Cell Sci 108( Pt 11): 3569-3579, 1995.
12. Ostergaard M, Rasmussen HH, Nielsen HV, Vorum H, Orntoft TF, Wolf H and Celis JE: Proteome profiling of bladder squamous cell carcinomas: identification of markers that define their degree of differentiation. Cancer Res 57: 4111-4117, 1997.
13. Melis R and White R: Characterization of colonic polyps by two-dimensional gel electrophoresis. Electrophoresis 20: 1055-1064, 1999.
14. Ferguson AT, Evron E, Umbricht CB, Pandita TK, Chan TA, Hermeking H, Marks JR, Lambers AR, Futreal PA, Stampfer MR and Sukumar S: High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci USA 97: 6049-6054, 2000.
15. Osada H, Tatematsu Y, Yatabe Y, Nakagawa T, Konishi H, Harano T, Tezel E, Takada M and Takahashi T: Frequent and histological type-specific inactivation of 14-3-3sigma in human lung cancers. Oncogene 21: 2418-2424, 2002.
16. Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J and Sukumar S: Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene 20: 3348-3353, 2001.
17. Suzuki H, Itoh F, Toyota M, Kikuchi T, Kakiuchi H and Imai K: Inactivation of the 14-3-3 sigma gene is associated with 5' CpG island hypermethylation in human cancers. Cancer Res 60: 4353-4357, 2000.
18. Iwata N, Yamamoto H, Sasaki S, Itoh F, Suzuki H, Kikuchi T, Kaneto H, Iku S, Ozeki I, Karino Y, Satoh T, Toyota J, Satoh M, Endo T and Imai K: Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma. Oncogene 19: 5298-5302, 2000.
19. Phelps RM, Johnson BE, Ihde DC, Gazdar AF, Carbone DP, McClintock PR, Linnoila RI, Matthews MJ, Bunn PA, Jr, Carney D, Minna JD and Mulshine JL: NCI-Navy Medical Oncology Branch cell line data base. J Cell Biochem Suppl 24: 32-91, 1996.
20. Gazdar AF, Kurvari V, Virmani A, Gollahon L, Sakaguchi M, Westerfield M, Kodagoda D, Stasny V, Cunningham HT, Wistuba II, Tomlinson G, Tonk V, Ashfaq R, Leitch AM, Minna JD and Shay JW: Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int J Cancer 78: 766-774, 1998.
21. Tsuchiya T, Tamura G, Sato K, Endoh Y, Sakata K, Jin Z, Motoyama T, Usuba O, Kimura W, Nishizuka S, Wilson KT, James SP, Yin J, Fleisher AS, Zou T, Silverberg SG, Kong D and Meltzer SJ: Distinct methylation patterns of two APC gene promoters in normal and cancerous gastric epithelia. Oncogene 19: 3642-3646, 2000.
22. Sirchia SM, Ferguson AT, Sironi E, Subramanyan S, Orlandi R, Sukumar S and Sacchi N: Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor ß2 promoter in breast cancer cells. Oncogene 19: 1556-1563, 2000.
23. Toyooka S, Toyooka KO, Harada K, Miyjima K., Makarla P, Sathyanarayana UG, Yin J, Sato F, Shivapurkar N, Meltzer SJ and Gazdar AF: Aberrant methylation of the CDH13 (Hcadherin) promoter region in colorectal cancers and adenomas. Cancer Res 62: 3382-3386, 2002.
24. Herrmann BG and Frischauf AM: Isolation of genomic DNA. Methods Enzymol 152: 180-183, 1987.
25. Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826, 1996.
26. Toyooka KO, Toyooka S, Maitra A, Feng Q, Kiviat NC, Smith A, Minna JD, Ashfaq R and Gazdar AF: Establishment and validation of real-time polymerase chain reaction method for CDH1 promoter methylation. Am J Pathol 161: 629-634, 2002.
27. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Danenberg PV and Laird PW: CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res 59: 2302-2306, 1999.
28. Jeronimo C, Usadel H, Henrique R, Oliveira J, Lopes C, Nelson WG and Sidransky D: Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organconfined prostate adenocarcinoma. J Natl Cancer Inst 93: 1747-1752, 2001.
29. Vercoutter-Edouart AS, Lemoine J, Le Bourhis X, Louis H, Boilly B, Nurcombe V, Revillion F, Peyrat JP and Hondermarck H: Proteomic analysis reveals that 14-3-3sigma is down-regulated in human breast cancer cells. Cancer Res 61: 76-80, 2001.
30. Aprelikova O, Pace AJ, Fang B, Koller BH and Liu ET: BRCA1 is a selective co-activator of 14-3-3 sigma gene transcription in mouse embryonic stem cells. J Biol Chem 276: 25647-25650, 2001.
31. Dhar S, Squire JA, Hande MP, Wellinger RJ and Pandita TK: Inactivation of 14-3-3sigma influences telomere behavior and ionizing radiation-induced chromosomal instability. Mol Cell Biol 20: 7764-7772, 2000.
32. Toyooka S, Toyooka KO, Maruyama R, Virmani AK, Girard L, Miyajima K, Harada K, Ariyoshi Y, T, T, Sugio K, Brambilla E, Gilcrease M, Minna JD and Gazdar AF: DNA methylation profiles of lung tumors. Mol. cancer therapeutics 1: 61-67, 2001.
33. Toyooka KO, Toyooka S, Virmani AK, Sathyanarayana UG, Euhus DM, Gilcrease M, Minna JD and Gazdar AF: Loss of expression and aberrant methylation of the CDH13 (Hcadherin) gene in breast and lung carcinomas. Cancer Res 61: 4556-4560, 2001.
34. Shivapurkar N, Toyooka S, Eby MT, Huang CX, Sathyanarayana UG, Cunningham HT, Reddy JL, Brambilla E, Takahashi T, Minna JD, Chaudhary PM and Gazdar AF: Differential inactivation of caspase-8 in lung cancers. Cancer Biol Ther 1: 65-69; discussion 70-61, 2002.